0.44
0.44 (0%)
As of Apr 17, 2025
Immunoprecise Antibodies Ltd. [IPA]
Source:
Company Overview
Immunoprecise Antibodies Ltd. is a leading biotherapeutic research and technology firm, distinguished by its proficiency in both in silico and wet lab methodologies. At the intersection of systems biology, multi-omics modeling, and complex artificial intelligence systems, the company has carved out a unique space within the field.
| Country | United States |
| Headquarters | vancouver |
| Phone Number | 6048060626 |
| Industry | manufacturing |
| CEO | Jennifer Bath |
| Website | www.ipatherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $24.5 |
| Operating Profit | $-29.1 |
| Net Income | $-27.2 |
| Net Cash | $-4.8 |
Profit Ratios
| Gross Margin | $12.1 |
| Operating Margin | -118.8 |
| Profit as % of Revenues | -44.4% |
| Profit as % of Assets | -64.3% |
| Profit as % of Stockholder Equity | -80.1% |
Management Effectiveness
| Return on Equity | -80.1% |
| Return on Assets | -45.3% |
| Turnover Ratio | 58% |
| EBITA | $-26.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $60 |
| Total Liabilities | $26.1 |
| Operating Cash Flow | $-4.2 |
| Investing Cash Flow | $-1.6 |
| Financing Cash Flow | $1 |
